#ACR23 Late-Breaking Abstr#L09 In a crowded market, you’ve got to stand out. Phase 2 RCT of LNK01001, a highly selective JAK1-i in China: improvement in ACR 20,50,70 vs PBO at WK12. Those in PBO who didn’t meet ACR20 improved after receiving Tx. Very low infections @RheumNow https://t.co/ZbJFNHOtFT

ARTIC REWIND: To taper or not? A#L07 #ACR23 @RheumNow RA pts taper TNFi in stable remission No taper group: 85% flare free in 3 yrs Taper grp: only 25% Lower Boolean 2.0 Remission rates Don't taper off a good thing! https://t.co/KnJrEfVFkV

Excellent session: Navigating CV risk for #inflammatory #arthritis - view from #cardiology #ACR23 14T118 @RheumNow @ACRheum https://t.co/WKhh0TonE8

Is #cardiology now a specialty like #rheumatology with bDMARDs? Many pathways discussed for CVD in #rheumatoid #arthritis. And biologics for lowering lipids too! #ACR23 ⁦@ACRheum⁩ ⁦@RheumNow⁩ 14T118. More overlap of pts over time! https://t.co/blv5GmHTGe

I continue to be underwhelmed by nintedanib, esp in RA-ILD Data from INBUILD-ON, f/u study to the INBUILD basket trial Persistent loss of FVC... wonder how pts would have done had they received an RA-active DMARD? Need H2H vs TNFs & real DMARDs @RheumNow #ACR23 Abstr 2158 https://t.co/56PgC6Uc67

Phase 2 RCT. Selective JAK1i LNK01001 in RA. 156 patients, 24 week (12 week PBO controlled). Abstr#L09 #ACR23 @RheumNow https://t.co/hHjL1yFH0H https://t.co/Qls4zRrRGH

The Fallacy of Biologic Treatment to Prevent RA It is time to stop fooling ourselves that we can prevent RA with our existing biologic agents. #ACR23 https://t.co/qHMW4HGkk2 https://t.co/l2Tn7hGtY3

• The Fallacy of Biologic Treatment to Prevent Rheumatoid Arthritis | RheumNow

Summary of diet effects in RA and SLE patients 👇 Dr. Sarah Patterson also shared nutrition resources for pts and clinicians https://t.co/ae6nLrLXca #ACR23 @Rheumnow @rheumarhyme @GerRheumDoc @doktora_ging https://t.co/8HhCHCTGLh

Great summary of the big takeaways yesterday at #ACR23. Always love talking to @KDAO2011 @EBRheum @RheumNow We get into the use of MTX, the safety on TNFs and what is in the purview of rheumatology practice https://t.co/jm0a8ndrsi